Financial News Feed

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 2) EXACT Sciences Corporation (NASDAQ: EXAS ) KemPharm Inc (NASDAQ: KMPH ) NeoGenomics, Inc. (NASDAQ: NEO ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Verastem Inc (NASDAQ: VSTM ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) (reported negative trial results ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Obseva Reports Positive Results For Long-Term Study Of Endometriosis Drug Obseva SA (NASDAQ: OBSV ) reported follow-up results from the Phase 2b EDELWEISS clinical trial of its oral gonadotropin-releasing hormone receptor antagonist linzagolix for treating endometriosis-related pelvic pain, showing that patients treating with linzagolix for 52 weeks saw maintenance of pelvic pain response rates, with the 75mg or the 200mg dose....

Read more

Vistagen Therapeutics Inc (NASDAQ: VTGN ) shares were nearly cut in half Thursday following adverse results from a Phase 2 study evaluating its treatment-resistant depression (TRD) drug candidate. What Happened Vistagen, a thinly traded nanocap, said Thursday after the market open that topline results from an exploratory Phase 2 study of its investigational drug AV-101 did not demonstrate significant difference from placebo on the primary outcome measure. The drug, which is being evaluated as a monotherapy in patients with TRD, was studied for the change from baseline in the Hamilton Depression Rating Scale total score. On the safety front, the company said that, consistent with … Full story available on Benzinga.com...

Read more

No summary available....

Read more

ABMD, FLR and W among premarket losers
01:13pm, Thursday, 02'nd May 2019
No summary available....

Read more

VistaGen Therapeutics, Inc. (:VTGN)’s shares are under review with key ownership changing hands of late. As company earnings reports continue to roll in, investors will be watching to see which comp...

Read more

VistaGen Therapeutics, Inc. (NasdaqCM:VTGN) of the General Retailers sector might have recently popped up on investor’s radars as the 54554 market cap company based out of United States of America r...

Read more

Following shares of Vistagen Therap. Com (VTGN), we have noted that the Percentage Price Oscillator is currently higher than the signal line. Traders watching this indicator will be looking for signs ...

Read more

Many individuals strive to expand their wealth by investing in the stock market. There are countless factors that come in to play when analyzing which stocks to invest in. Along with all the tangible ...

Read more

In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGN), with a price target of ... The post VistaGen Therapeutics (VTGN) Gets a Buy Rat...

Read more

PH94B has potential to be the First FDA-Approved PRN Treatment for Social Anxiety Disorder New Findings Presented at the 2019 Anxiety and Depression Association of America Annual Conference SOUTH S......

Read more

Both VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Anchiano Therapeutics Ltd (NASDAQ:ANCN) compete on a level playing field in the Biotechnology industry. We...

Read more

Vistagen Therap. Com (VTGN) are in focus as we look at near-term expected movement. The reading from the 40-day commodity channel index is currently Hold. The CCI indicator is mainly used to identify ...

Read more

The Shareholder Yield of VistaGen Therapeutics, Inc. (NasdaqCM:VTGN) is -0.421438. The Shareholder Yield is a tool used by investors to see how much money shareholders are receiving from a firm throug...

Read more

Vistagen Therap. Com (VTGN) touched 1.28 on a recent bid indicating that the Tenkan line is still hovering above the Kijun Sen. This represents bullish momentum for the shares. Whether or not the shar...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank